Glimicron - General Information:

An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion. [PubChem]

Pharmacology:

Glimicron is a second generation sulphonylurea which acts as a hypoglycemic agent. It stimulates beta cells of the islet of Langerhans in the pancreas to release insulin. It also enhances peripheral insulin sensitivity. Overall it potentiates insulin release and improves insulin dynamics.

Additional information about Glimicron

Glimicron Indication: For the treatment of Diabetes mellitus
Mechanism Of Action: Glimicron binds to the beta cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the beta cells. This opens voltage-dependent calcium channels in the beta cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.
Drug Interactions: Acebutolol The beta-blocker decreases the symptoms of hypoglycemia
Atenolol The beta-blocker decreases the symptoms of hypoglycemia
Betaxolol The beta-blocker decreases the symptoms of hypoglycemia
Bevantolol The beta-blocker decreases the symptoms of hypoglycemia
Bisoprolol The beta-blocker decreases the symptoms of hypoglycemia
Carteolol The beta-blocker decreases the symptoms of hypoglycemia
Carvedilol The beta-blocker decreases the symptoms of hypoglycemia
Esmolol The beta-blocker decreases the symptoms of hypoglycemia
Labetalol The beta-blocker decreases the symptoms of hypoglycemia
Metoprolol The beta-blocker decreases the symptoms of hypoglycemia
Nadolol The beta-blocker decreases the symptoms of hypoglycemia
Oxprenolol The beta-blocker decreases the symptoms of hypoglycemia
Penbutolol The beta-blocker decreases the symptoms of hypoglycemia
Pindolol The beta-blocker decreases the symptoms of hypoglycemia
Practolol The beta-blocker decreases the symptoms of hypoglycemia
Propranolol The beta-blocker decreases the symptoms of hypoglycemia
Sotalol The beta-blocker decreases the symptoms of hypoglycemia
Timolol The beta-blocker decreases the symptoms of hypoglycemia
Aspirin The salicylate increases the effect of sulfonylurea
Bismuth Subsalicylate The salicylate increases the effect of sulfonylurea
Salicylate-magnesium The salicylate increases the effect of sulfonylurea
Salicylate-sodium The salicylate increases the effect of sulfonylurea
Salsalate The salicylate increases the effect of sulfonylurea
Trisalicylate-choline The salicylate increases the effect of sulfonylurea
Repaglinide Similar mode of action - questionable association
Rifampin Rifampin decreases the effect of sulfonylurea
Tranylcypromine The MAO inhibitor increases the effect of the hypoglycemic agent
Phenelzine The MAO inhibitor increases the effect of the hypoglycemic agent
Isocarboxazid The MAO inhibitor increases the effect of the hypoglycemic agent
Phenylbutazone Phenylbutazone increases the effect of the hypoglycemic agent
Glucosamine Possible hyperglycemia
Dicumarol The agent increases the effect of sulfonylurea
Chloramphenicol The agent increases the effect of sulfonylurea
Clofibrate The agent increases the effect of sulfonylurea
Food Interactions: Take without regard to meals.
Avoid alcohol.
Generic Name: Gliclazide
Synonyms: 1-(3-Azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea; 1-(Hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea; Gliclazida [INN-Spanish]; Gliclazidum [INN-Latin]; N-(4-Methylbenzenesulfonyl)-N'-(3-azabicyclo(3.3.0)oct-3-yl)urea
Drug Category: Hypoglycemic Agents; Sulfonylureas
Drug Type: Small Molecule; Approved
Other Brand Names containing Gliclazide: Diamicron; Glimicron; Nordialex;
Absorption: Rapidly and well absorbed but may have wide inter- and intra-individual variability.
Toxicity (Overdose): LD50=3000 mg/kg (orally in mice)
Protein Binding: Not Available
Biotransformation: Hepatic
Half Life: 11 hours (Campbell DB et al.,Diabetes Res Clin Pract.;14:S21-36)
Dosage Forms of Glimicron: Tablet Oral
Tablet, extended release Oral
Chemical IUPAC Name: 1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea
Chemical Formula: C15H21N3O3S
Gliclazide on Wikipedia: http://en.wikipedia.org/wiki/Gliclazide
Organisms Affected: Humans and other mammals

Bookmark or Share this page


»Get link codes for this page«
(HTML/BB code)



Search by name browsing our [A-Z] index:

ABCDEFGHI
JKLMNOPQR
STUVWXYZ

Search by Categories:

See a list of all drugs for sale »

Top5 meds in current month:

*based on number of page views on Flexyx

Visit our friends:

brand and generic ed pills Russian Scientific Center for Restorative Traumatology and Orthopaedics in the name of academician G.A.Ilizarov

Related News

Fri, 15 Jul 2011
Business Week - DAINIPPON SUMITOMO PHARMA CO (4506:JP) - Stock Quote & Company Profile - BusinessWeek
This segment also offers GLIMICRON and MELBIN that are oral hypoglycemics. LONASEN and LULLAN, which are antipsychotic agents. AmBisome, a therapeutic agent for systemic fungal infection. ALMARL, a therapeutic agent for hypertension, angina pectoris, and arrhythmia. TAGAMET, a H2-receptor antagonist.
Source: investing.businessweek.com »

Mon, 09 May 2011
Dainippon Sumitomo Pharma announces the launch of SUREPOST®, a rapid-acting insulin secretagogue - News Release - ...
DSP promotes several products which have different mechanisms of action for type 2 diabetes, including METGLUCO®, a biguanide oral hypoglycemic drug, SEIBULE®, an alpha-glucosidase inhibitor, and GLIMICRON®, a sulfonylurea oral hypoglycemic.
Source: www.ds-pharma.com »



Thanks for visiting us!